| Style | Citing Format |
|---|---|
| MLA | Norozi M, et al.. "Higher Rate of Epstein–Barr Virus Co-Infection With Sars-Cov-2 Compared to Adenovirus, Influenza A, and B Viruses in Northeast Iran." Future Virology, vol. 21, no. 2, 2026, pp. 111-120. |
| APA | Norozi M, Pirjane S, Azimi SA, Letafati A, Taghiabadi Z, Ebrahimi M, Mehravar F, Tabarraei A, Razavi Nikoo H (2026). Higher Rate of Epstein–Barr Virus Co-Infection With Sars-Cov-2 Compared to Adenovirus, Influenza A, and B Viruses in Northeast Iran. Future Virology, 21(2), 111-120. |
| Chicago | Norozi M, Pirjane S, Azimi SA, Letafati A, Taghiabadi Z, Ebrahimi M, Mehravar F, Tabarraei A, Razavi Nikoo H. "Higher Rate of Epstein–Barr Virus Co-Infection With Sars-Cov-2 Compared to Adenovirus, Influenza A, and B Viruses in Northeast Iran." Future Virology 21, no. 2 (2026): 111-120. |
| Harvard | Norozi M et al. (2026) 'Higher Rate of Epstein–Barr Virus Co-Infection With Sars-Cov-2 Compared to Adenovirus, Influenza A, and B Viruses in Northeast Iran', Future Virology, 21(2), pp. 111-120. |
| Vancouver | Norozi M, Pirjane S, Azimi SA, Letafati A, Taghiabadi Z, Ebrahimi M, et al.. Higher Rate of Epstein–Barr Virus Co-Infection With Sars-Cov-2 Compared to Adenovirus, Influenza A, and B Viruses in Northeast Iran. Future Virology. 2026;21(2):111-120. |
| BibTex | @article{ author = {Norozi M and Pirjane S and Azimi SA and Letafati A and Taghiabadi Z and Ebrahimi M and Mehravar F and Tabarraei A and Razavi Nikoo H}, title = {Higher Rate of Epstein–Barr Virus Co-Infection With Sars-Cov-2 Compared to Adenovirus, Influenza A, and B Viruses in Northeast Iran}, journal = {Future Virology}, volume = {21}, number = {2}, pages = {111-120}, year = {2026} } |
| RIS | TY - JOUR AU - Norozi M AU - Pirjane S AU - Azimi SA AU - Letafati A AU - Taghiabadi Z AU - Ebrahimi M AU - Mehravar F AU - Tabarraei A AU - Razavi Nikoo H TI - Higher Rate of Epstein–Barr Virus Co-Infection With Sars-Cov-2 Compared to Adenovirus, Influenza A, and B Viruses in Northeast Iran JO - Future Virology VL - 21 IS - 2 SP - 111 EP - 120 PY - 2026 ER - |